Genting Xinyao announced today that the summary meeting of the “Comprehensive Evaluation Project for Clinical Application of Erracycline” initiated and hosted by the Expert Committee on Clinical Application and Drug Resistance Evaluation of Antimicrobials of the National Health Commission will be held in Beijing. According to the final project report released at the same time, eracycline showed good efficacy and safety in treating 3,369 infected patients from various departments such as ICU, hematology, transplantation, and respiratory departments, especially in patients with lung infections caused by various pathogens such as carbapene-resistant Acinetobacter baumannii and Klebsiella pneumoniae; the overall efficacy rate for 3 days of treatment with eracycline was 91.1%. At the end of treatment, patients had an average fever of 3.2 days.

Genting Xinyao announced today that the summary meeting of the “Comprehensive Evaluation Project for Clinical Application of Erracycline” initiated and hosted by the Expert Committee on Clinical Application and Drug Resistance Evaluation of Antimicrobials of the National Health Commission will be held in Beijing. According to the final project report released at the same time, eracycline showed good efficacy and safety in treating 3,369 infected patients from various departments such as ICU, hematology, transplantation, and respiratory departments, especially in patients with lung infections caused by various pathogens such as carbapene-resistant Acinetobacter baumannii and Klebsiella pneumoniae; the overall efficacy rate for 3 days of treatment with eracycline was 91.1%. At the end of treatment, patients had an average fever of 3.2 days.